Director Danina Fisher of Hepion Pharmaceuticals, Inc. filed a statement of changes in beneficial ownership on October 27, 2026, reporting the acquisition of stock options dated October 23, 2026.

Key Highlights

  • Reporting person: Danina Fisher, serving as a Director of Hepion Pharmaceuticals, Inc.
  • Options acquired: 510,000 stock options with an exercise price of $0.14 per share, acquired on October 23, 2026.
  • Vesting schedule: 42,500 options vest in equal amounts monthly over 12 months from the date of grant, according to the filing.
  • Option expiration: The options expire on October 23, 2036, giving a 10-year term from grant date.
  • Price of derivative security: The filing reports the price of the derivative security as $0.
  • Total derivative holdings: Following the transaction, Fisher beneficially owns 809,000 derivative securities directly.

Director Option Grant Details for Hepion Pharmaceuticals

According to the filing, Danina Fisher, a director of Hepion Pharmaceuticals, Inc. (OTC:HEPA), acquired 510,000 stock options on October 23, 2026, with an exercise price of $0.14 per share. The underlying security is common stock of Hepion Pharmaceuticals. Hepion Pharmaceuticals is a pharmaceutical company, and the grant reflects compensation activity associated with Fisher's board service. The filing notes that the price of the derivative security was $0 at the time of the transaction.

The filing further discloses that the options follow a monthly vesting schedule, with 42,500 options vesting in equal amounts each month over a 12-month period beginning on the grant date of October 23, 2026. The options are set to expire on October 23, 2036. Following this transaction, Fisher's total beneficial ownership of derivative securities stands at 809,000, held directly. The filing was signed by Danina Fisher and submitted on October 27, 2026.

What Was Disclosed

The filing discloses that Director Danina Fisher of Hepion Pharmaceuticals, Inc. received 510,000 stock options at an exercise price of $0.14, vesting monthly over 12 months, expiring October 23, 2036, bringing her total derivative holdings to 809,000 shares.